Cytogel Pharma welcomes those with interest in partnering with us as we advance the science and knowledge toward transforming pain management. We believe that our innovative progress on CYT-1010 and other endomorphins could provide the kind of effective and safe pain relief for patients that has not been achieved before, which presents a very interesting opportunity for a licensing agreement.
Our lead compound is the first in a new class of drugs, with a novel mechanism of action to enter human clinical development. CYT-1010 has proven to be more potent than morphine with an improved side effect profile of less respiratory depression and less potential for causing addiction.
We are delighted that we have received authorization to begin Phase 2 clinical studies on CYT-1010, following a successful Phase 1 study in humans. As such, we are preparing to begin these studies at this time.
Cytogel is also considering additional relationships to expand the development of the company's hydrogel technologies with applications for enhancing drug delivery. These hydrogels may be made temperature- and/or pH-sensitive and may carry many times their weight in drug, potentially improving control of drug release and precision of delivery.
If you are interested in exploring a collaboration or corporate partnership with Cytogel Pharma or would like additional information, please contact us directly.